Potential indications: wet macular degeneration, diabetes macular edema

Description:

1. For the treatment of wet age-related macular degeneration and diabetes macular edema.

2. Targeting and VEGF-A inhibit VEGF pathway, inhibit endothelial cell proliferation, neovascularization and vascular permeability, and alleviate retinal edema.

3. Foreign similar drugs have been listed; The clinical results showed that the primary endpoint was non inferior and the curative effect was equivalent to that of arbasip; It was superior to Compaq on the secondary endpoint. Compared with the same target drugs, the administration frequency is once every 3 months, which is conducive to improve patient compliance and reduce medical costs.

4. This product adopts Escherichia coli to express inclusion body renaturation, which has technical barriers.